JP2011516478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516478A5 JP2011516478A5 JP2011502995A JP2011502995A JP2011516478A5 JP 2011516478 A5 JP2011516478 A5 JP 2011516478A5 JP 2011502995 A JP2011502995 A JP 2011502995A JP 2011502995 A JP2011502995 A JP 2011502995A JP 2011516478 A5 JP2011516478 A5 JP 2011516478A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- effective
- cytostatic
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 230000001085 cytostatic Effects 0.000 claims 3
- 239000000824 cytostatic agent Substances 0.000 claims 3
- 150000002402 hexoses Chemical class 0.000 claims 3
- -1 hydrate Substances 0.000 claims 3
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 2
- 102100006435 CSF3 Human genes 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 2
- 229960001592 Paclitaxel Drugs 0.000 claims 2
- 108010001645 Rituximab Proteins 0.000 claims 2
- 108010010691 Trastuzumab Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229930003347 taxol Natural products 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- 102100001249 ALB Human genes 0.000 claims 1
- 101710027066 ALB Proteins 0.000 claims 1
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229960002756 Azacitidine Drugs 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229960004689 BCG Vaccine Drugs 0.000 claims 1
- 108010005144 Bevacizumab Proteins 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960004117 Capecitabine Drugs 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 108010022830 Cetuximab Proteins 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N Coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 1
- 210000003022 Colostrum Anatomy 0.000 claims 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229940108890 Emend Drugs 0.000 claims 1
- 108010074604 Epoetin Alfa Proteins 0.000 claims 1
- 229960003388 Epoetin alfa Drugs 0.000 claims 1
- 229960005073 Erlotinib Hydrochloride Drugs 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 235000014066 European mistletoe Nutrition 0.000 claims 1
- 229960004177 Filgrastim Drugs 0.000 claims 1
- 108010029961 Filgrastim Proteins 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- 150000004924 Gefitinib derivatives Chemical class 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 1
- 229960003180 Glutathione Drugs 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 229940087603 Grape Seed Extract Drugs 0.000 claims 1
- ZGCHATBSUIJLRL-UHFFFAOYSA-N Hydrazine sulfate Chemical compound NN.OS(O)(=O)=O ZGCHATBSUIJLRL-UHFFFAOYSA-N 0.000 claims 1
- 229960003685 Imatinib mesylate Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 108090000177 Interleukin-11 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229960002404 Palifermin Drugs 0.000 claims 1
- 108010061219 Panitumumab Proteins 0.000 claims 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims 1
- 241000320380 Silybum Species 0.000 claims 1
- 235000010841 Silybum marianum Nutrition 0.000 claims 1
- 229960003454 Tamoxifen Citrate Drugs 0.000 claims 1
- 229940099419 Targretin Drugs 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 Thalidomide Drugs 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960002190 Topotecan Hydrochloride Drugs 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 241000221012 Viscum Species 0.000 claims 1
- 229960000237 Vorinostat Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 229940050528 albumin Drugs 0.000 claims 1
- 230000002022 anti-cellular Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960001372 aprepitant Drugs 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 229940095076 benzaldehyde Drugs 0.000 claims 1
- 150000003935 benzaldehydes Chemical class 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 1
- 235000021277 colostrum Nutrition 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 235000002532 grape seed extract Nutrition 0.000 claims 1
- 239000012493 hydrazine sulfate Substances 0.000 claims 1
- 229910000377 hydrazine sulfate Inorganic materials 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 235000001411 milk thistle Nutrition 0.000 claims 1
- 229960000801 nelarabine Drugs 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative Effects 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 claims 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 239000001717 vitis vinifera seed extract Substances 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
Claims (8)
- 前記ベンズアルデヒド誘導体が4,6−0−ベンジリジン−D−グルコピラノシルオキシである、請求項1に記載の組成物。
- 前記対象における癌を治療または予防するために、前記式Iのベンズアルデヒド誘導体化合物との組み合わせ製剤または協調治療計画において有効な二次的細胞増殖抑制剤もしくは他の補助的治療薬をさらに含む、請求項1又は2に記載の組成物。
- 前記二次的細胞増殖抑制剤もしくは補助的治療薬が、アザシチジン、ベバシズマブ、ボルテゾミブ、カペシタビン、セツキシマブ、クロファラビン、ダサチニブ、デシタビン、ドセタキセル、エメンド、エルロチニブ塩酸塩、エキセメスタン、フルベストラント、ゲフィチニブ、ゲムシタビン塩酸塩、メシル酸イマチニブ、イミキモド、レナリドマイド、レトロゾール、ネララビン、オキサリプラチン、パクリタキセル、パクリタキセル・アルブミン安定化小粒子製剤、パリフェルミン、パニツムマブ、ペガスパルガーゼ、ペメトレキセド二ナトリウム、リツキシマブ、トシル酸ソラフェニブ、リンゴ酸スニチニブ、クエン酸タモキシフェン、タルグレチン、テモゾロミド、サリドマイド、トポテカン塩酸塩、トラスツズマブ、BCGワクチン、インターロイキン−2、インターフェロンα、リツキシマブ、トラスツズマブ、フィルグラスチム、G−CSF、エポエチンアルファ、エリスロポエチン、IL−11、オプレルベキン、ボリノスタット、コエンザイムQ、パラジウム−リポ酸錯体、抗新生物薬、軟骨、硫酸ヒドラジン、ミルクシスル、電解質、グルタチオン、アルカリ水、ポリMVA(登録商標)、ブドウ種子抽出物、免疫グロブリン、初乳、酸化剤およびヤドリギからなる群から選択される、請求項3に記載の組成物。
- 前記二次的細胞増殖抑制剤もしくは補助的治療薬がポリMVAである、請求項3に記載の組成物。
- 前記二次的細胞増殖抑制剤もしくは補助的治療薬がアルカリ水である、請求項3に記載の組成物。
- 放射線療法、インスリン増強療法、ゴンザレスレジメン、食事療法、鍼治療および外科手術から選択される補助的療法と共に用いられることを特徴とする、請求項1〜6に記載の組成物。
- 前記細胞増殖阻害に有効な量の前記式Iのベンズアルデヒド誘導体化合物が、前記対象における腫瘍サイズを約10%〜約90%減少させるのに有効である、請求項1〜7に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4221008P | 2008-04-03 | 2008-04-03 | |
US61/042,210 | 2008-04-03 | ||
PCT/US2009/002134 WO2009145841A1 (en) | 2008-04-03 | 2009-04-03 | Compositions and methods for immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011516478A JP2011516478A (ja) | 2011-05-26 |
JP2011516478A5 true JP2011516478A5 (ja) | 2012-05-24 |
Family
ID=41267359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011502995A Pending JP2011516478A (ja) | 2008-04-03 | 2009-04-03 | 免疫療法のための組成物および方法 |
Country Status (12)
Country | Link |
---|---|
US (5) | US20090281047A1 (ja) |
EP (1) | EP2271350A4 (ja) |
JP (1) | JP2011516478A (ja) |
CN (1) | CN102046180A (ja) |
AU (1) | AU2009251848A1 (ja) |
CA (1) | CA2757437A1 (ja) |
IL (1) | IL208445A0 (ja) |
MX (1) | MX339451B (ja) |
NZ (1) | NZ588668A (ja) |
RU (1) | RU2010144744A (ja) |
WO (1) | WO2009145841A1 (ja) |
ZA (1) | ZA201007830B (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
AU2009335943A1 (en) | 2008-12-19 | 2013-10-24 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis |
AU2010274097B2 (en) | 2009-07-13 | 2016-06-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
US20140155344A1 (en) * | 2010-06-07 | 2014-06-05 | Neil P. Desai | Combination therapy methods for treating proliferative diseases |
US20130171279A1 (en) * | 2012-01-04 | 2013-07-04 | Physicianrx, Llc | Composition for Reducing Side- and After-Effects of Cancer Treatment |
CN103156951A (zh) * | 2013-04-11 | 2013-06-19 | 太仓市胜舟生物技术有限公司 | 一种治疗b细胞淋巴瘤的组合药物 |
EP3085372B1 (en) * | 2013-12-20 | 2021-07-28 | Vergara Campillo, Ramiro Moises | Combination of pyridoxine, folic acid and magnesium ions for treating cancer |
US20170224654A1 (en) | 2016-02-04 | 2017-08-10 | Stem Cell Theranostics, Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
WO2018027029A1 (en) * | 2016-08-03 | 2018-02-08 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
EP3665180A4 (en) * | 2017-08-07 | 2021-09-01 | Cognate 3 LLC | COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN ANAEROBIC CELLS AND ASSOCIATED CLINICAL METHODS FOR THE TREATMENT OF CANCER AND PATHOGENIC INFECTIONS |
WO2022200833A1 (en) * | 2021-03-25 | 2022-09-29 | 2B-Shvat Ltd. | Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus |
JP7018531B1 (ja) | 2021-04-30 | 2022-02-10 | 潤 齋藤 | Axl阻害剤 |
WO2023161862A2 (en) * | 2022-02-24 | 2023-08-31 | Robinov Shmuel | Methods of use of benzaldehyde compositions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882314A (en) * | 1985-12-02 | 1989-11-21 | Rikagaku Kenkyusho | A composition and method of treating selected malignant conditions |
US6407071B1 (en) * | 1998-06-04 | 2002-06-18 | Co-Enzyme Technology Ltd. | Method and composition for treating malignant cells |
NO309305B1 (no) * | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
-
2009
- 2009-04-03 JP JP2011502995A patent/JP2011516478A/ja active Pending
- 2009-04-03 WO PCT/US2009/002134 patent/WO2009145841A1/en active Application Filing
- 2009-04-03 MX MX2010010866A patent/MX339451B/es active IP Right Grant
- 2009-04-03 AU AU2009251848A patent/AU2009251848A1/en not_active Abandoned
- 2009-04-03 EP EP09755204A patent/EP2271350A4/en not_active Withdrawn
- 2009-04-03 RU RU2010144744/15A patent/RU2010144744A/ru not_active Application Discontinuation
- 2009-04-03 CN CN2009801205538A patent/CN102046180A/zh active Pending
- 2009-04-03 NZ NZ588668A patent/NZ588668A/xx not_active IP Right Cessation
- 2009-04-03 CA CA2757437A patent/CA2757437A1/en not_active Abandoned
- 2009-04-03 US US12/418,342 patent/US20090281047A1/en not_active Abandoned
-
2010
- 2010-10-03 IL IL208445A patent/IL208445A0/en unknown
- 2010-11-02 ZA ZA2010/07830A patent/ZA201007830B/en unknown
-
2011
- 2011-08-19 US US13/213,819 patent/US20110311476A1/en not_active Abandoned
- 2011-08-19 US US13/213,933 patent/US20110311477A1/en not_active Abandoned
- 2011-08-19 US US13/214,022 patent/US20110311478A1/en not_active Abandoned
-
2012
- 2012-06-17 US US13/525,317 patent/US20120251490A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011516478A5 (ja) | ||
RU2010144744A (ru) | Композиции и способы иммунотерапии | |
JP2020019812A5 (ja) | ||
JP2020514271A5 (ja) | ||
RU2018120318A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
US11730736B2 (en) | Anticancer agents | |
JP2021191750A5 (ja) | ||
JP2018517686A5 (ja) | ||
JP2012153722A5 (ja) | ||
ES2877712T3 (es) | Terapias combinadas para su uso en el tratamiento del cáncer de mama | |
JP2012158602A5 (ja) | ||
ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
HRP20220351T1 (hr) | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene | |
JP2010525057A5 (ja) | ||
JP6198286B2 (ja) | 癌の処置のためのイソフラボノイド化合物および方法 | |
JP2013531068A (ja) | 4−ヨード−3−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法 | |
KR101575706B1 (ko) | 암 치료용 선택적인 ep4 수용체 길항제 | |
JP2014511383A5 (ja) | ||
JP2017505785A5 (ja) | ||
SI3174881T1 (en) | (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases | |
JP2012522841A5 (ja) | ||
JP2020514344A5 (ja) | ||
CN110642910B (zh) | 胸苷衍生物及其制备方法和用途 | |
JP2013526579A5 (ja) | ||
JP2005509663A5 (ja) |